Neuropeptide Y Y1 Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy
Neuropeptide Y Y1 Receptors Meditate Targeted Delivery of Anticancer Drug with Encapsulated Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy
复制标题
神经肽Y Y-1受体介导将抗癌药物与封装的纳米颗粒高选择性地靶向递送至乳腺癌细胞及其治疗乳腺癌的潜力
DOI：
10.1021/acsami.5b00270
复制
发表时间：
2015-03-11
影响因子：
9.5
通讯作者：
Wu, Aiguo
中科院分区：
文献类型：
--
作者：
Li, Juan;Shen, Zheyu;Wu, Aiguo
通过使基于纳米颗粒的药物递送系统能够以高选择性主动靶向癌细胞，活性靶向分子在纳米颗粒用于抗癌药物递送的应用中引起了极大的关注。然而，大多数活性靶向分子在乳腺癌治疗中的临床应用受到限制，这是由于其受体在乳腺肿瘤中的低表达或在正常和肿瘤乳腺组织中的共表达。在这里，神经肽Y Y-1受体配体PNBL-NPY，作为一种新的靶向分子，与抗癌药物阿霉素包裹白蛋白纳米粒缀合，以研究Y-1受体对载药纳米粒递送到乳腺癌细胞的影响及其用于乳腺癌治疗的潜力。PNBL-NPY可以主动识别并结合乳腺癌细胞表面显著过表达的Y-1受体，载药纳米颗粒通过内化直接递送到癌细胞中。由于正常乳腺细胞仅表达Y-2受体，该系统具有高度选择性，能够将乳腺癌细胞与正常细胞区分开来。预期本研究可为开发基于Y-1受体的纳米药物递送系统提供指导，以实现更安全、更有效的乳腺癌治疗。
By enabling nanoparticle-based drug delivery system to actively target cancer cells with high selectivity, active targeted molecules have attracted great attention in the application of nanoparticles for anticancer drug delivery. However, the clinical application of most active targeted molecules in breast cancer therapy is limited, due to the low expression of their receptors in breast tumors or coexpression in the normal and tumor breast tissues. Here, a neuropeptide Y Y-1 receptors ligand PNBL-NPY, as a novel targeted molecule, is conjugated with anticancer drug doxorubicin encapsulating albumin nanoparticles to investigate the effect of Y-1 receptors on the delivery of drug-loaded nanoparticles to breast cancer cells and its potential for breast cancer therapy. The PNBL-NPY can actively recognize and bind to the Y-1 receptors that are significantly overexpressed on the surface of the breast cancer cells, and the drug-loaded nanoparticles are delivered directly into the cancer cells through internalization. This system is highly selective and able to distinguish the breast cancer cells from the normal cells, due to normal breast cells that express Y-2 receptors only. It is anticipated that this study may provide a guidance in the development of Y-1 receptor-based nanoparticulate drug delivery system for a safer and more efficient breast cancer therapy.